By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Serono, Inc. 

One Technology Place

Rockland  Massachusetts  02370  U.S.A.
Phone: 781-982-9000 or 800-283-8088 Fax: n/a


Serono, Inc. is a leader in the US biotechnology arena, integrating cutting-edge science with unparalleled patient support systems to improve people’s lives. Through its focus on specialized therapeutic areas, including reproductive health, metabolic endocrinology and neurology, as well as oncology as an emerging area of expertise, Serono, Inc. is committed to discovering and developing innovative products that address unmet medical needs.

As the US affiliate of Serono S.A., a global biotechnology leader headquartered in Geneva, Switzerland, Serono, Inc. is an integral part of driving the growth and success of the company’s global business. In 2004, North American product sales accounted for approximately 40% of worldwide revenue.

Serono, Inc. employs more than 450 people at its world-class research and commercial facility in Rockland, MA, including more than 90 scientists dedicated to understanding diseases and developing the treatments of the future.

The company’s U.S. products are Rebif® (interferon beta-1a), Novantrone® (mitoxantrone for injection concentrate), Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection), Ovidrel® (choriogonadotropin alfa injection), Crinone 8%® (progesterone gel), Cetrotide® (cetrorelix acetate for injection), Serostim® [somatropin (rDNA origin) for injection], Saizen® [somatropin (rDNA origin) for injection] and Zorbtive™ [somatropin (rDNA origin) for injection].

In 2004, Serono SA achieved worldwide revenues of $2.4 billion, and a net income of $494.2m, making it the third largest biotech company in the world. The company operates in 45 countries, and its products are sold in over 90 countries. Bearer shares of Serono S.A., the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).

Key Statistics

Ownership: Public

Web Site: Serono, Inc.
Employees: 450
Symbol: SRA


Company News
Merck KGaA (MKGAF.PK) Announces Serono Preliminary Figures for 2006 3/1/2007 11:06:42 AM
ZymoGenetics, Inc. (ZGEN) And Serono Begin Phase 2 Clinical Trial With Atacicept In Rheumatoid Arthritis 12/20/2006 3:15:04 PM
Micromet Receives $10 Million Milestone Payment From Serono, Inc. (SRA) For Completion Of Phase 2 Clinical Trials 12/4/2006 11:37:36 AM
Serono, Inc. (SRA) And Newron Pharmaceuticals Announce Global Development And Commercialization Agreement For Safinamide 10/16/2006 9:33:17 AM
BioMarin Pharmaceutical Inc. (BMRN) And Serono, Inc. (SRA) Announce Data On Phenoptin In PKU To Be Presented At The 56th Annual Meeting Of The American Society of Human Genetics 9/12/2006 10:36:43 AM
Dyax Corp. (DYAX) And Serono, Inc. (SRA) Enter Into Library License And Funded Research Agreements For Discovery Of Therapeutic Antibodies 9/7/2006 12:21:20 PM
Serono, Inc. (SRA) Announces Results From Pivotal Phase III Clinical Trial Of Its Proprietary Recombinant Human Growth Hormone In The Treatment Of HARS At The XVI International AIDS Conference; Trial Achieves Goal 8/18/2006 8:17:13 AM
ZymoGenetics, Inc. (ZGEN) And Serono Present Positive Results of TACI-Ig Phase 1b Trial in Rheumatoid Arthritis At EULAR Meeting 6/26/2006 3:07:42 PM
Serono International S.A. (SRA) Announces Termination of Discussions Concerning A Sale Of The Company 4/10/2006 11:35:53 AM
BioMarin Pharmaceutical Inc. (BMRN) And Serono, Inc. (SRA) Announce Positive Results From Phase 3 Clinical Study Of Phenoptin For PKU; Shares Up 3/16/2006 10:16:48 AM